Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer
Crossref DOI link: https://doi.org/10.1007/s00280-015-2799-3
Published Online: 2015-06-07
Published Print: 2015-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ueda, Shinya
Kawakami, Hisato
Nishina, Shinichi
Sakiyama, Tsutomu
Nonagase, Yoshikane
Okabe, Takafumi
Tamura, Takao
Nakagawa, Kazuhiko
Text and Data Mining valid from 2015-06-07